Skip to main content

Table 2 Clinical information (n = 26; IVIG intravenous immunoglobulins, CIDP chronic inflammatory demyelinating polyneuropathy, INCAT Inflammatory Neuropathy Cause and Treatment, GS glucocorticosteroids)

From: Differences in peripheral myelin antigen-specific T cell responses and T memory subsets in atypical versus typical CIDP

   typical atypical p-values atypical vs. typical
Sex male 3/9 (33%) 14/17 (82%) 0.013
  female 6/9 (66%) 3/17 (18%)  
Age (years) mean 61.0 57.2 0.512
  range 32-78 33-74  
Previous treatment None 3/9 (33%) 9/17 (53%) 0.429a
  IVIG 4/9 (44%) 6/17 (35%) 0.652a
  Steroid 2/9 (22%) 2/17 (12%) 0.547a
Time since diagnosis mean 4.1 4.2 0.860
(years) range 1-8 1-7  
INCAT mean 3.2 2.3 0.045
  Range <1-8 <1-7  
Disease activity range 1-5 1-3  
  active-unstable 6/9 (66%) 14/17 (82%) 1.000b
  active-stable 1/9 (11%) 0/17 (0%) 0.333b
  in remission 2/9 (22%) 3/17 (18%) 1.000b
Therapy response responder 9/9 (100%) 8/17 (47%) 0.022
  non-responder 0/9 (0%) 9/17 (53%)  
  1. Fishers exact test for sex, previous treatment, disease activity and therapy response
  2. acompared versus treatment naïve patients
  3. bcompared versus remission state; unpaired t-test for age and INCAT score; Mann-Whitney test for time since diagnosis